ArticleJAMA network open2025
Trends in Prostate Cancer Incidence and Mortality Rates.
Article in JAMA network open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A Systematic Review of the Economic Burden of Prostate Cancer: Direct and Indirect Cost Perspectives.PharmacoEconomics · 2026Pooled it
- Using a Community-Embedded Screening and Navigation Framework to Engage High-Risk Men in Prostate Cancer Early Detection: Five Years of the Men's Health Awareness Summit in Oklahoma.Journal of racial and ethnic health disparities · 2026Article
- Medical Management of Modifiable Risks: Improving Survival in High-Risk Prostate Cancer Patients Receiving Brachytherapy.Journal of clinical medicine · 2026Article
- Population-level cancer trends among solid organ transplant recipients in the United States during 1995-2021.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2026Article
- Shared Decision-Making for Prostate Cancer Screening in Racial and Ethnic Minority Populations: A Systematic Review.Journal of racial and ethnic health disparities · 2026Article
- Twenty years of age-standardized prostate cancer mortality in Kazakhstan (2005-2024): joinpoint model and geographical hot spot and cold spot analysis.BMC public health · 2026Observational
- Genetic Polymorphisms and Antioxidant Reactions in Prostate Cancer.International journal of molecular sciences · 2026Review
- Screening policy changes and prostate cancer epidemiology: 20-year trends in diagnosis, treatment, incidence, and mortality.World journal of urology · 2026Article
- Cancer statistics, 2026: divergent trends and the implementation gap.Nature reviews. Clinical oncology · 2026Article
- Prostate Cancer Incidence, Mortality, and Survival in Switzerland.JAMA network open · 2026Article
- Renal cell carcinoma incidence and mortality in California: a population-based study of sociodemographic patterns and temporal trends from 1988 through 2019.Lancet regional health. Americas · 2026Article
- The diagnostic accuracy of [99mTc]Tc-PSMA SPECT/CT for recurrent prostate cancer based on individual patient attributes.European journal of nuclear medicine and molecular imaging · 2026Article
- Artificial Intelligence in Prostate MRI: Addressing Current Limitations Through Emerging Technologies.Journal of magnetic resonance imaging : JMRI · 2026Review
- The impact of different exercise modes on prostate cancer: a Bayesian network meta-analysis.Scientific reports · 2026Article
- Spatiotemporal patterns and clustering of prostate cancer incidence in China: a Bayesian modeling study of cancer registry data.BMC public health · 2026Article
- The volume of Gleason grade group 1 prostate cancer at biopsy predicts unfavorable pathology but not upgrading after radical prostatectomy.International urology and nephrology · 2026Article
- ONX-0914 Suppresses Hormone-Sensitive Prostate Cancer by Promoting O-GlcNAcylation-Mediated Stabilization of TCF7L1.Oncology research · 2026Article
- Effect of radical prostatectomy on anxiety, depression, and quality of life in patients diagnosed with prostate cancer.World journal of psychiatry · 2025Article
- A Multi-Modal Transfer Learning Framework to Reduce Health Disparities in Prostate Adenocarcinoma.bioRxiv : the preprint server for biology · 2025Article
- Role of APOC1 and NOP16 in the diagnosis of prostate cancer.BMC urology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Incidence of distant stage prostate cancer is increasing in the United States. Research is needed to understand trends by social and geographic factors. Objective: To examine trends in prostate cancer incidence and mortality rates in California by stage, age, race and ethnicity, and region. Design, Setting, and Participants: This cohort study used mortality data from the California Cancer Registry and California Department of Public Health's Center for Health Statistics, and incidence data from the National Cancer Institute Surveillance, Epidemiology, and End Results program and the US Census. The dataset for these analyses was released in April 2024. Participants included males residing in California between 2004 and 2021. Analyses were conducted from April to October 2024. Exposures: Stage at diagnosis, age, race and ethnicity, and region of California. Main Outcomes and Measures: The delay-adjusted incidence rates and mortality rates were calculated and age-adjusted to the 2000 US standard population. Annual percentage changes (APC) were calculated using NCI's Joinpoint Regression Program. Results: Between 2004 and 2021, there were 387 636 prostate cancer cases (27 938 distant stage) and 58 754 prostate cancer deaths in California. In this study, 203 038 cases (52.4%) occurred among males aged 55 to 69 years, and 153 884 (39.7%) occurred among males 70 years or older. The distribution of race and ethnicity among cases was: 1031 American Indian or Alaska Native (0.3%); 31 366 Asian American, Native Hawaiian, and Pacific Islander (8.1%); 66 695 Hispanic or Latino (17.2%); 36 808 non-Hispanic Black (9.5%); 238 229 non-Hispanic White (61.5%); and 13 507 unknown or other races (3.5%). On average, the incidence of distant prostate cancer increased 6.7% (95% CI, 6.2% to 7.3%) per year between 2011 and 2021. By race and ethnicity, the APC ranged from 6.5% (95% CI, 4.2% to 13.4%) among Asian American, Native Hawaiian, and Pacific Islander males between 2011 and 2021 to 8.0% (95% CI, 6.9% to 9.5%) among Hispanic males between 2014 and 2021. In 9 of the 10 California regions, the incidence of distant prostate cancer increased by approximately 6% or more per year. Prostate cancer mortality rates declined 2.6% per year between 2004 and 2012 but plateaued between 2012 to 2021 (APC, 0.1%; 95% CI, -0.6% to 1.6%). The plateau in mortality occurred across ages, races and ethnicities, and regions. Conclusions and relevance: In this cohort study among California residents, the incidence of distant stage prostate cancer increased throughout the state between 2011 and 2021. Mortality rates plateaued between 2012 and 2021, ending previous decades of decline. Implementation of more effective prostate cancer screening strategies are critically needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.